NSE · MANKIND · Pharmaceuticals
Mankind Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,964 Cr with net profit ₹558 Cr — a 18.84% net margin, versus 27.64% the period before.
Shareholding
As of 2026-09-30
- Promoter72.62%
- Public2.45%
- FII9.37%
- DII15.56%
1,63,770 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.38× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #6 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,20,172 Cr | 33.25 | 5.03 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,16,997 Cr | 23.96 | 4.32 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,15,735 Cr | 105.83 | 21.84 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹1,09,343 Cr | 39.06 | 2.82 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,09,063 Cr | 30.47 | 3.17 | 11.27% | 12.06% |
| Mankind Pharma Limited(this company) | ₹1,03,365 Cr | 48.45 | 6.34 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹93,643 Cr | 24.77 | 2.47 | 9.25% | 10.7% |
| Lupin Limited | ₹89,264 Cr | 14.99 | 3.98 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹63,944 Cr | 20.49 | 6.08 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹60,715 Cr | 26.64 | 4.39 | 16.66% | 14.31% |
AI analysis
AI-generated · google/gemini-2.5-flashMankind Pharma Limited is listed with a market capitalization of Rs 105967 Cr. The company reported revenue of Rs 14636.43 Cr with a growth of 19% and a net profit margin of 13.4%. Its P/E ratio stands at 190.91, and EPS is Rs 48.78. The company's debt-to-equity ratio is 0.48.
Positives
- +Revenue grew by 19% to Rs 14636.43 Cr.
- +The profit margin is 13.4% of revenue.
- +The debt-to-equity ratio is 0.48, indicating moderate leverage.
- +Promoter holding of 72.6304% is substantial.
- +There are no promoter shares pledged.
Negatives
- −The P/E ratio is 190.91, which may indicate a high valuation.
- −Promoter holding decreased from 76.5% in December 2023 to 72.6304% in June 2026.
- −Public shareholding decreased from 7.26409999999998% in December 2023 to 2.52730000000001% in June 2026.
Financial Performance
In the period ending March 2026, Mankind Pharma Limited recorded revenue of Rs 14636.43 Cr, marking a 19% growth. The company's net profit for the same period was Rs 1912.93 Cr. Quarterly revenue for March 2026 was Rs 3442.93 Cr with a net profit of Rs 554.35 Cr. The EBITDA for March 2026 was Rs 821.09 Cr.
Profitability & Returns
Mankind Pharma Limited achieved a profit margin of 13.4%. The Return on Equity (ROE) for the company is 11.74%, and the Return on Capital Employed (ROCE) is 13.126%. The basic EPS stands at Rs 48.78. The P/E ratio is 190.91.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.48. The book value per share is Rs 394.69. No information regarding other specific balance sheet items is provided in the data.
Ownership & Pledges
The public shareholding stands at 2.5273%. The total institutional holding is 24.8423%. There are no promoter pledges reported.
Shareholding History
Promoter holding has decreased from 74.88% in March 2024 to 72.6304% in June 2026. DII holding has increased from 11.1384% in March 2024 to 15.389% in June 2026. FII holding has decreased from 9.8736% in March 2024 to 9.4533% in June 2026. The number of shareholders has increased from 135,116 in March 2024 to 166,715 in June 2026.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.